Palisade Bio (NASDAQ: PALI) shares skyrocketed by almost 85% on Monday after a biopharmaceutical company announced positive preclinical data for lead program PALI-2108 at the 2024 Crohn’s & Colitis Congress.
Palisade Bio (PALI) has made public the positive preclinical data of its primary asset, PALI-2108. This announcement was made during the Crohn’s & Colitis Congress, which took place in Las Vegas, NV, from January 25-27, 2024.
The preclinical data was displayed on a poster titled; “Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment.”
PALI-2108, a prodrug under development by the Company, is an orally administered, colon-specific phosphodiesterase-4B (PDE4B) inhibitor. It is developed for patients with moderate to severe active ulcerative colitis (UC).
Key Findings from Preclinical Studies
The Crohn’s and Colitis Foundation has presented results from multiple preclinical studies of PALI-2108. The Company’s research aims to overcome the drawbacks of existing PDE4 inhibitors, including CNS toxicity and systemic distribution, which frequently result in therapy discontinuation.
In preclinical trials, PALI-2108 showed encouraging results. A significant decrease in the disease activity index (DAI) score was observed in a DSS-induced UC mouse model compared to the control group. Notably, the body weight loss was mitigated in certain dosage groups, indicating potential for targeted effectiveness.
The unique design of PALI-2108, which includes a galactose-derived sugar component, permits limited absorption until it is cleaved by the colonic bacterial enzyme β-glucuronidase. This feature guarantees localized bioactivation, resulting in colon-specific distribution with limited systemic exposure, as validated by a tissue distribution study. The colon/plasma AUC ratio surpassing 200 further underscores PALI-2108’s predilection for the colon.
Furthermore, the Company’s research indicates colon-specific bioactivation in oxazolone colitis-induced mice, insignificant plasma levels in duodenal and ileal tissue, and similar target engagement to other PDE4 inhibitors. A tolerated dose study in dogs showed no CNS toxicity or vomiting over effective doses, addressing a critical issue related to oral administration.
In summary, the Company’s preclinical studies revealed that PALI-2108 exhibited:
- Local bioactivation;
- Colon-specific distribution;
- Similar target engagement to other PDE4 inhibitors;
- Dose-dependent efficacy in a mouse UC model; and
- No systemic toxicity in dogs and a large therapeutic window due to local activation.
Palisade Bio (NASDAQ: PALI) Stock Performance
PALI stock soared 84.62% on Monday. The traders had exchanged hands with 135,301,530 (135.30 million) shares compared to the average daily trading volume of 292.22 thousand.
Salman Akhtar is a finance, stocks, and technology journalist with years of experience across various news organizations. He has contributed his expertise to outlets such as 24NewsHD, TrimFeed, The Voice Pakistan, and TheTechBasic. Salman is passionate about making complex topics accessible to a broad audience. His dedication to delivering accurate and timely information has established him as a trusted voice in the industry. Read Full Bio
